Publications
5600 Results
- Journal / Conference
- Blood 132:1992; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777
Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 with Long-Term Follow Up
- Journal / Conference
- Blood 132:437; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), accepted, oral/plenary
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2906
Prospective Study of Minimal Residual Disease (MRD) Status and Outcome After Complete Remission (CR) Following Intensive Remission Induction Therapy in Older Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age > 60 Years
- Journal / Conference
- Blood 132:3995American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2906
FLT3-ITD Mutations Are Prevalent in Older Adults with Acute Myeloid Leukemia (AML) and Significantly Impact Outcome After Intensive Therapy: Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age > 60 Years
- Journal / Conference
- Blood 132:435; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA)
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10603
Prognostic impact of insertion site in acute myeloid leukemia with FLT3 internal tandem duplication: results from the RATIFY study (Alliance)
- Journal / Conference
- Blood 132:1534; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10603
Comprehensive molecular profiling of FLT3-mutated acute myeloid leukemia (AML) patients treated within the RATIFY trial
- Journal / Conference
- Blood 132:2668; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10603
RATIFY: Prognostic Impact of FLT3 Tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy
- Journal / Conference
- Blood 132:1877; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0120
African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma. Results of a Prospective Study SWOG S0120
- Journal / Conference
- Global Adolescent & Young Adult Cancer Congress (Dec 4-6, 2018, Sydney, Australia), oral presentation
- Year
- 2018
- Research Committee(s)
- Cancer Care Delivery
Analysis of Accrual Patterns of Adolescent & Young Adult (AYA) Patients to A National Cooperative Research Group Over 25 Years: The SWOG Experience
- Journal / Conference
- Blood 132:LBA-4; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), oral
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E1912
A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)
- Journal / Conference
- Nature Communications Nov 5;9(1):4616
- Year
- 2018
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- PMID
- PMID30397198
- PMC
- PMC6218483
- Study Number(s)
- S0000, SWOG-9217